Randomised comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic

Submission date	Recruitment status No longer recruiting	Prospectively registered		
22/07/2005		☐ Protocol		
Registration date	Overall study status	Statistical analysis plan		
22/07/2005	Completed	[X] Results		
Last Edited	Condition category	Individual participant data		
06/02/2015	Infections and Infestations			

Plain English summary of protocol

Not provided at time of registration

Contact information

Type(s)

Scientific

Contact name

Dr Mayfong Mayxay

Contact details

Mahosot Hospital
Microbiology Laboratory
Mahosot Road
Vientiane
Lao People's Democratic Republic
PO Box 5
+856 (0)21 250752
Mayfong@tropmedres.ac

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

065146

Study information

Scientific Title

Randomised comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic

Study objectives

Randomised comparison of chloroquine plus sulfadoxine-pyrimethamine versus artesunate plus mefloquine versus artemether-lumefantrine in the treatment of uncomplicated falciparum malaria in the Lao People's Democratic Republic.

Ethics approval required

Old ethics approval format

Ethics approval(s)

Not provided at time of registration

Study design

Randomised controlled trial

Primary study design

Interventional

Secondary study design

Randomised controlled trial

Study setting(s)

Not specified

Study type(s)

Treatment

Participant information sheet

Health condition(s) or problem(s) studied

Malaria

Interventions

A randomised comparison of three oral antimalarial combinations.

- 1. Chloroquine plus sulfadoxine-pyrimethamine
- 2. Artesunate plus mefloquine
- 3. Artemether-lumefantrine

42-day follow-up period.

Intervention Type

Drug

Phase

Not Applicable

Drug/device/biological/vaccine name(s)

Chloroquine, sulfadoxine-pyrimethamine, artesunate, mefloquine, artemether-lumefantrine

Primary outcome measure

Parasitological and clinical responses to treatment.

Secondary outcome measures

- 1. Parasite and fever clearance times
- 2. Gametocytaemia
- 3. Changes in haematocrit following antimalarial treatment

Overall study start date

14/07/2002

Completion date

17/10/2003

Eligibility

Key inclusion criteria

- 1. Patients or their quardians gave fully informed written consent
- 2. Had a density of asexual P. falciparum of 5000 to 200,000 per microlitre of blood
- 3. Were aged more than one year
- 4. Had an axillary temperature of more than 37.5°C or history of fever in the previous three days
- 5. Were likely to stay in the hospital until parasite clearance and complete the 42-day follow up period

Participant type(s)

Patient

Age group

Mixed

Sex

Both

Target number of participants

330

Key exclusion criteria

- 1. Pregnant or lactating women
- 2. Patients who took a full course of any antimalarials in the previous three days
- 3. Patients with signs of severe malaria
- 4. Those with history of allergy or contraindication to the study drugs

Date of first enrolment

14/07/2002

Date of final enrolment

17/10/2003

Locations

Countries of recruitment

Lao People's Democratic Republic

Study participating centre

Mahosot Hospital

Vientiane Lao People's Democratic Republic PO Box 5

Sponsor information

Organisation

University of Oxford (UK)

Sponsor details

University Offices Wellington Square Oxford England United Kingdom OX1 2JD

Sponsor type

University/education

Website

http://www.ox.ac.uk

ROR

https://ror.org/052gg0110

Funder(s)

Funder type

Charity

Funder Name

Wellcome Trust

Alternative Name(s)

Funding Body Type

Private sector organisation

Funding Body Subtype

International organizations

Location

United Kingdom

Results and Publications

Publication and dissemination plan

Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration

Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
Results article	Results	15/10/2004		Yes	No